Literature DB >> 24085772

The national drug abuse treatment clinical trials network data share project: website design, usage, challenges, and future directions.

Dikla Shmueli-Blumberg1, Lian Hu, Colleen Allen, Michael Frasketi, Li-Tzy Wu, Paul Vanveldhuisen.   

Abstract

BACKGROUND: There are many benefits of data sharing, including the promotion of new research from effective use of existing data, replication of findings through re-analysis of pooled data files, meta-analysis using individual patient data, and reinforcement of open scientific inquiry. A randomized controlled trial is considered as the 'gold standard' for establishing treatment effectiveness, but clinical trial research is very costly, and sharing data is an opportunity to expand the investment of the clinical trial beyond its original goals at minimal costs.
PURPOSE: We describe the goals, developments, and usage of the Data Share website (http://www.ctndatashare.org) for the National Drug Abuse Treatment Clinical Trials Network (CTN) in the United States, including lessons learned, limitations, and major revisions, and considerations for future directions to improve data sharing.
METHODS: Data management and programming procedures were conducted to produce uniform and Health Insurance Portability and Accountability Act (HIPAA)-compliant de-identified research data files from the completed trials of the CTN for archiving, managing, and sharing on the Data Share website.
RESULTS: Since its inception in 2006 and through October 2012, nearly 1700 downloads from 27 clinical trials have been accessed from the Data Share website, with the use increasing over the years. Individuals from 31 countries have downloaded data from the website, and there have been at least 13 publications derived from analyzing data through the public Data Share website. LIMITATIONS: Minimal control over data requests and usage has resulted in little information and lack of control regarding how the data from the website are used. Lack of uniformity in data elements collected across CTN trials has limited cross-study analyses.
CONCLUSIONS: The Data Share website offers researchers easy access to de-identified data files with the goal to promote additional research and identify new findings from completed CTN studies. To maximize the utility of the website, ongoing collaborative efforts are needed to standardize the core measures used for data collection in the CTN studies with the goal to increase their comparability and to facilitate the ability to pool data files for cross-study analyses.

Entities:  

Mesh:

Year:  2013        PMID: 24085772      PMCID: PMC3994893          DOI: 10.1177/1740774513503522

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  29 in total

1.  Sharing research data urged.

Authors:  C Norman
Journal:  Science       Date:  1985-08-16       Impact factor: 47.728

2.  Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults.

Authors:  Li-Tzy Wu; Marvin S Swartz; Jeng-Jong Pan; Bruce Burchett; Paolo Mannelli; Chongming Yang; Dan G Blazer
Journal:  Gen Hosp Psychiatry       Date:  2012-07-21       Impact factor: 3.238

3.  Comparison of opiate-primary treatment seekers with and without alcohol use disorder.

Authors:  Bryan Hartzler; Dennis M Donovan; Zhen Huang
Journal:  J Subst Abuse Treat       Date:  2010-07-03

4.  Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials.

Authors:  Bryan Hartzler; Dennis M Donovan; Zhen Huang
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

5.  Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies.

Authors:  Jeffrey E Korte; Kathryn M Magruder; Codruta C Chiuzan; Sarah L Logan; Therese Killeen; Dipankar Bandyopadhyay; Kathleen T Brady
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

6.  Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.

Authors:  Li-Tzy Wu; Walter Ling; Bruce Burchett; Dan G Blazer; Chongming Yang; Jeng-Jong Pan; Bryce B Reeve; George E Woody
Journal:  Drug Alcohol Depend       Date:  2011-04-17       Impact factor: 4.492

7.  Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study.

Authors:  Li-Tzy Wu; Jeng-Jong Pan; Dan G Blazer; Betty Tai; Maxine L Stitzer; George E Woody
Journal:  J Subst Abuse Treat       Date:  2010-06

8.  Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study.

Authors:  Li-Tzy Wu; Dan G Blazer; Maxine L Stitzer; Ashwin A Patkar; Jack D Blaine
Journal:  Am J Addict       Date:  2008 Jul-Aug

9.  Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study.

Authors:  Li-Tzy Wu; Dan G Blazer; Ashwin A Patkar; Maxine L Stitzer; Paul G Wakim; Robert K Brooner
Journal:  Am J Addict       Date:  2009 May-Jun

10.  Towards agreement on best practice for publishing raw clinical trial data.

Authors:  Iain Hrynaszkiewicz; Douglas G Altman
Journal:  Trials       Date:  2009-03-18       Impact factor: 2.279

View more
  1 in total

1.  Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study.

Authors:  Niranjan S Karnik; Cynthia I Campbell; Megan E Curtis; David A Fiellin; Udi Ghitza; Kathryn Hefner; Yih-Ing Hser; R Kathryn McHugh; Sean M Murphy; Sterling M McPherson; Landhing Moran; Larissa J Mooney; Li-Tzy Wu; Dikla Shmueli-Blumberg; Matisyahu Shulman; Robert P Schwartz; Kari A Stephens; Katherine E Watkins; John Marsden
Journal:  Trials       Date:  2021-01-28       Impact factor: 2.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.